{
    "xml": "<topic id=\"PHP81556\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/budelin-novolizer\" basename=\"budelin-novolizer\" title=\"Budelin Novolizer\">\n<title>Budelin Novolizer<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP83114\" outputclass=\"indicationsAndDose\" rev=\"1.14\" parent=\"/clinical-medicinal-product-information/budelin-novolizer\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of asthma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>200&#8211;800&#8239;micrograms twice daily, dose is adjusted as necessary.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Alternative in mild to moderate asthma, for patients previously stabilised on a twice daily dose</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>200&#8211;400&#8239;micrograms once daily (max. per dose 800&#8239;micrograms), to be taken in the evening.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP83124\" outputclass=\"patientAndCarerAdvice\" rev=\"1.11\" parent=\"/clinical-medicinal-product-information/budelin-novolizer\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on adminstration of <i>Budelin NovolizerA</i>\n<tm tmtype=\"reg\"/>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81556",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/budelin-novolizer",
    "basename": "budelin-novolizer",
    "title": "Budelin Novolizer",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of asthma",
                        "html": "Prophylaxis of asthma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of powder"
                    ],
                    "textContent": "By inhalation of powder",
                    "html": "By inhalation of powder"
                },
                "adult": [
                    {
                        "textContent": "200&#8211;800 micrograms twice daily, dose is adjusted as necessary.",
                        "html": "<p>200&#8211;800&#8239;micrograms twice daily, dose is adjusted as necessary.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Alternative in mild to moderate asthma, for patients previously stabilised on a twice daily dose",
                        "html": "Alternative in mild to moderate asthma, for patients previously stabilised on a twice daily dose"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of powder"
                    ],
                    "textContent": "By inhalation of powder",
                    "html": "By inhalation of powder"
                },
                "adult": [
                    {
                        "textContent": "200&#8211;400 micrograms once daily (max. per dose 800 micrograms), to be taken in the evening.",
                        "html": "<p>200&#8211;400&#8239;micrograms once daily (max. per dose 800&#8239;micrograms), to be taken in the evening.</p>"
                    }
                ]
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on adminstration of Budelin NovolizerA .",
                "html": "<p>Patients or carers should be given advice on adminstration of <i>Budelin NovolizerA</i>\n<tm tmtype=\"reg\"/>.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}